


Castleman Disease Treatment Market worth \$719.87 million by 2030 - Exclusive Report by 360iResearch

The Global Castleman Disease Treatment Market to grow from USD 259.37 million in 2022 to USD 719.87 million by 2030, at a CAGR of 13.60%.

PUNE, MAHARASHTRA, INDIA,
November 15, 2023 /
EINPresswire.com/ -- The "[Castleman Disease Treatment Market](#) by Disease Type (Multicentric Castleman's Disease, Unicentric Castleman's Disease), Indication (Angiofollicular Lymph Node Hyperplasia, Angiomatous Lymphoid, Castleman Tumor), Treatment, Application - Global Forecast 2023-2030" report has been added to 360iResearch.com's offering.



The Global Castleman Disease Treatment Market to grow from USD 259.37 million in 2022 to USD 719.87 million by 2030, at a CAGR of 13.60%.

Request a Free Sample Report @ https://www.360iresearch.com/library/intelligence/castleman-disease-treatment?utm_source=einpresswire&utm_medium=referral&utm_campaign=sample

Castleman disease treatment involves a specialized healthcare procedure to manage a rare illness called Castleman disease, which is characterized by the overgrowth of cells in the body's lymph nodes, causing a variety of symptoms from fever and fatigue to abnormal weight loss. Recent years have observed an increased prevalence of rare diseases, including Castleman disease, necessitating enhanced treatment options. The understanding of Castleman disease has advanced over the years, leading to the development of targeted therapies. Ongoing research focuses on identifying biomarkers, understanding the underlying pathophysiology, and discovering novel treatment options. Some treatments for Castleman disease have received orphan drug designation, which provides incentives for pharmaceutical companies to develop

therapies for rare diseases. However, the high cost of drug development, limited treatment options, and strict regulatory compliance impede the expansion of treatment. Healthcare professionals, researchers, and advocacy groups are collaborating on a global scale to improve the diagnosis, management, and treatment of Castleman disease.

Disease type: Need for rapid deployment of treatment strategies for multicentric Castleman's disease due to the chances of systemic organ failure

Multicentric Castleman's disease (MCD) refers to the disease condition that causes lymph node enlargement in multiple regions of the patient's body. There are three categories of MCD- Polyneuropathy, organomegaly, endocrinopathy, M proteins, and skin changes (POEMS)-associated MCD, human herpesvirus-8 (HHV-8)-associated MCD, and idiopathic MCD. Treatment for multicentric Castleman disease generally involves medicines and other therapies to control cell overgrowth. Specific treatment may also depend on the extent of the disease and whether the patient has human immunodeficiency virus infection (HIV), human herpesvirus-8 (HHV-8) infection, or both. Unicentric Castleman's disease (UCD) refers to a disorder that affects a single lymph node in the patient's body, usually in the chest or abdomen. Unicentric Castleman disease can be treated by surgically removing the diseased lymph node.

Treatment: Advancements in chemotherapy treatments leading to expanding adoption of Castleman disease treatment options

Antiviral medications are used to target harmful viruses. The antiviral drugs are used to ease disease symptoms. Chemotherapy refers to the practice of utilizing a drug or chemical treatment to kill fast-growing cancer cells in a patient's body. Low-dose single-agent chemotherapy treatment options, such as daily oral etoposide⁵⁹ or intermittent etoposide or vinblastine, have been utilized for MCD. Corticosteroids are powerful anti-inflammatory drugs that can mitigate disease symptoms. Systemic corticosteroids can provide symptomatic relief but do not predictably reduce tumor size. Immunotherapy takes advantage of the body's natural defenses to fight the disease. Monoclonal antibodies refer to proteins made in a laboratory that bind to one pathogenic antigen only. In HHV-8-associated MCD, treatment with rituximab is highly effective. For some patients with HIV infection, antiretroviral therapy (ART) should be included with the rituximab. Radiation therapy refers to a cancer treatment that uses bursts of radiation to target and kill cancer cells and shrink tumors. In unicentric Castleman disease, radiotherapy radiation therapy is a viable treatment option because of its high response rates.

Indication: Rising adoption of Castleman's disease treatment options for tackling angiomatous lymphoid cases

Angiofollicular lymph node hyperplasia is associated with prolonged fever, anemia, weight loss, splenomegaly, and hypergammaglobulinemia. Angiomatous lymphoid hamartomas or pseudolymphomas have been reported most commonly within the chest and are usually mistaken for thymic tumors of lymphomatous tissue. It is a rare manifestation where immunomodulatory treatment is often utilized. Castleman tumor is an unusual mediastinal lymph node hyperplasia that resembles thymoma. The characteristic histologic characteristics include an onion skin arrangement of the lymphocytes in nodules and an unusual vasculature

with marked capillary proliferation. Giant benign lymphoma is the most common non-epithelial benign tumor occurring in the large intestine. It is usually observed in the rectum as a single reddish-purple or grey, rounded polyp varying in diameter from a few millimeters to 3–4 centimeters. Giant lymph node hyperplasia is a nonneoplastic lymphoproliferative disorder of unknown etiology that is usually observed in the chest. The morphological recognition of this disease is based on a combination of various histological features. Angiomyomatous hamartoma of lymph nodes (AMH-LN) refers to an unusual benign proliferation of smooth muscle, blood vessels, collagenous stroma, and adipocytes.

Application: Preference for ambulatory surgical centers due to provision of optimum patient care

Ambulatory surgical centers (ASCs) refer to modern medical facilities that aim to provide same-day surgical care, including diagnostic and preventive procedures. These centers have gradually become popular for the treatment of Castleman disease due to their perceived medical efficiency and the reduced waiting times involved in scheduling a treatment. The hospital segment continues to remain a significant contributor to Castleman disease treatment owing to the intensity of care that comes with the complex nature of disease management.

Regional Insights:

The Americas, particularly the U.S. and Canada, has a relatively well-established infrastructure for rare disease diagnosis and treatment, including Castleman disease. There are specialized medical centers and experts focused on the condition, and patient advocacy groups and research institutes have contributed to the awareness and advancements in diagnosis and treatment. In Asia, access to castle treatment is limited when compared to the other regions; however, the government investment in healthcare development has significantly strived toward a more focused approach to rare diseases. Major cities in the region offer advanced diagnostic and treatment options, and small-scale academic institutes in China, Japan, and India are investing heavily in R&D activities. In Europe, the government promotes stakeholder cooperation in healthcare and research activities, benefiting the treatment of Castleman disease. The European Medicines Agency has been working on reviewing improved medications and approving them to elevate the provision and access to Castleman treatment to patients in the region.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Castleman Disease Treatment Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in the Castleman Disease Treatment Market. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

Key Company Profiles:

The report delves into recent significant developments in the Castleman Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Agilent Technologies, Inc., Amgen Inc., Artiva Biotherapeutics, Inc., Bayer AG, Bio-Rad Laboratories, Inc., Biogen Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cadila Pharmaceuticals Limited, Celltrion Healthcare Co.,Ltd., F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Glenmark Pharmaceuticals S.A., Johnson & Johnson Services, Inc., LGM Pharma, Merck & Co., Inc., Novartis AG, Octapharma AG, Pfizer, Inc., Recordati Group Company, Recordati S.p.A., Sanofi S.A., Sartorius AG, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., and Viatris Inc..

Inquire Before Buying @ https://www.360iresearch.com/library/intelligence/castleman-disease-treatment?utm_source=einpresswire&utm_medium=referral&utm_campaign=inquire

Market Segmentation & Coverage:

This research report categorizes the Castleman Disease Treatment Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Disease Type, market is studied across Multicentric Castleman's Disease and Unicentric Castleman's Disease. The Multicentric Castleman's Disease is projected to witness significant market share during forecast period.

Based on Indication, market is studied across Angiofollicular Lymph Node Hyperplasia, Angiomatous Lymphoid, Castleman Tumor, Giant Benign Lymphoma, Giant Lymph Node Hyperplasia, and Hamartoma of the Lymphatics. The Castleman Tumor is projected to witness significant market share during forecast period.

Based on Treatment, market is studied across Antiviral Drugs, Chemotherapy, Corticosteroids, Immunotherapy, Monoclonal Antibodies, and Radiation Therapy. The Antiviral Drugs is projected to witness significant market share during forecast period.

Based on Application, market is studied across Ambulatory Surgical Centers and Hospitals. The Ambulatory Surgical Centers is projected to witness significant market share during forecast

period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 36.55% in 2022, followed by Americas.

Key Topics Covered:

1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
6. Castleman Disease Treatment Market, by Disease Type
7. Castleman Disease Treatment Market, by Indication
8. Castleman Disease Treatment Market, by Treatment
9. Castleman Disease Treatment Market, by Application
10. Americas Castleman Disease Treatment Market
11. Asia-Pacific Castleman Disease Treatment Market
12. Europe, Middle East & Africa Castleman Disease Treatment Market
13. Competitive Landscape
14. Competitive Portfolio
15. Appendix

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Castleman Disease Treatment Market?
2. Which are the products/segments/applications/areas to invest in over the forecast period in the Castleman Disease Treatment Market?
3. What is the competitive strategic window for opportunities in the Castleman Disease Treatment Market?
4. What are the technology trends and regulatory frameworks in the Castleman Disease Treatment Market?
5. What is the market share of the leading vendors in the Castleman Disease Treatment Market?
6. What modes and strategic moves are considered suitable for entering the Castleman Disease Treatment Market?

Read More @ https://www.360iresearch.com/library/intelligence/castleman-disease-treatment?utm_source=einpresswire&utm_medium=referral&utm_campaign=analyst

Mr. Ketan Rohom
360iResearch
+ 1 530-264-8485
ketan@360iresearch.com

This press release can be viewed online at: <https://www.einpresswire.com/article/668717043>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.